Actelion Pharmaceuticals US, Inc.
5000 Shoreline Court
South San Francisco
28 articles with Actelion Pharmaceuticals US, Inc.
Owlstone Medical Enters into a Strategic Collaboration with Actelion to Develop a Breath-Based Test to Help Facilitate Early Detection of Pulmonary Hypertension
Owlstone Medical announces a strategic collaboration with Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson and a global leader in pulmonary arterial hypertension, to discover and validate a breath-based test to help facilitate the early diagnosis of pulmonary hypertension and its subtypes.
New Post-hoc Analysis Shows Adding UPTRAVI® (selexipag) Versus Placebo Improved Long-Term Clinical Outcomes Regardless of Time of Treatment Initiation, and Demonstrated an Even More Pronounced Treatment Effect When Initiated Early
Actelion presents latest post-hoc analysis from the GRIPHON study - the largest randomized, controlled, outcome trial ever conducted in patients with pulmonary arterial hypertension (PAH) [20-May-2019] ALLSCHWIL, Switzerland , May 20, 2019 /PRNewswire/ -- Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has presented
Third Pole Therapeutics Announces Inhaled Nitric Oxide Strategic Collaboration with Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson
Third Pole Therapeutics announced that it has entered into a strategic collaboration to work with Actelion Pharmaceuticals Ltd, a Janssen pharmaceutical company of Johnson & Johnson.
Interim Analysis Showed Treatment with OPSUMIT® (macitentan) Associated with Significant Improvement in Right Ventricular (RV) Function and Pulmonary Vascular Resistance (PVR) in Patients with Pulmonary Arterial Hypertension (PAH)
Actelion Pharmaceuticals US, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today an interim analysis from the Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension (REPAIR) study of OPSUMIT®
Actelion Receives Complete Response Letter from U.S. FDA for OPSUMIT® (Macitentan) Supplemental New Drug Application
Actelion Pharmaceuticals Ltd announced it has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for OPSUMIT® (macitentan) in the treatment of adults with inoperable chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) to improve pulmonary vascular resistance (PVR) and exercise capacity.
Analytics 4 Life® and Actelion Enter Research Agreement to Develop New Diagnostics for Pulmonary Hypertension
Research endeavor marks a clinical research expansion of the CorVista® platform
Azafaros, today announced the closing of a seed financing round. BioGeneration Ventures (BGV) is the founding investor.
Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT® (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Filing supported by data from MERIT-1 trial evaluating OPSUMIT in adults with inoperable CTEPH which showed significant improvements in pulmonary vascular resistance and six-minute walk distance (6MWD) compared with ongoing background therapy
Actelion Pharmaceuticals US, Inc. Release: Europe's Largest Biopharmaceutical Company Takes Big Leap into Procurement-Powered Business Performance With Zycus
Auxilium Pharmaceuticals and Actelion Pharmaceuticals US, Inc. Announce Approval of XIAFLEX® In Canada
Auxilium Pharmaceuticals and Actelion Pharmaceuticals US, Inc. Enter a Collaboration Agreement for XIAFLEX® in Canada, Australia, Brazil and Mexico for Up to $68.5 Million
Actelion Pharmaceuticals US, Inc. Release: Pulmonary Hypertension Association Names Dr. Ronald Oudiz Recipient of 2011 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care
Updated U.S. Product Labeling for Actelion Ltd.'s Veletri (Epoprostenol for Injection) Allows Patients to Prepare This Medication Up to a Week in Advance of Use for Pulmonary Arterial Hypertension
Actelion Pharmaceuticals US, Inc. Pays Eur 10 Million for Option to Buy Trophos for up to Eur 195 Million
Pulmonary Hypertension Association Names Actelion Pharmaceuticals US, Inc. Recipient of 2010 Corporation of the Year Award